J&J reports 75% tumor response rate with novel prostate cancer therapy
· seekingalpha.com · popularity 20/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at seekingalpha.com →
Summary
Johnson & Johnson (J&J) said that an early-stage trial of JNJ-6143 (previously HLD-0915) found that the novel oral Regulated Induced Proximity …
Found in: Investing. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 4.